Comment

COVID-19 vaccine manufacturing, supply and administration programs January 22, 2021

The speed of the US immunisation program is accelerating with the country administering 1.6 million doses in the past day. The country has now administered 19.1 million doses but it has distributed 39.9 million.

Bionomics-BMS combination completes trial treatment phase January 22, 2021

The phase two trial involves the use of Bionomics' BNC105 in combination with Bristol Myers Squibb’s PBS-listed immunotherapy OPDIVO (nivolumab) in patients with metastatic colorectal cancer.

Almac Group survey reveals pandemic impact on clinical trial activity January 22, 2021

A new survey from biopharmaceutical contract development and manufacturing organisation Almac Group has provided insight into how global companies are managing their clinical trial programs through the COVID-19 pandemic.

Industry slams last minute Trump move to cut medicine coverage January 22, 2021

The US-based industry has slammed the former Trump administration after what was virtually its final act was to strip protections from a key government prescription benefit program meaning insurers can cut the number of medicines they cover.

Queensland research institute in new cell therapy trial January 21, 2021

Researchers at the QIMR Berghofer Medical Research Institute in Brisbane have launched a clinical trial of a new cellular immunotherapy treatment.

This is what being 'among the first in the world' looks like January 21, 2021

The Australian government recently said it would 'bring forward' the country's COVID-19 immunisation program to mid-February. Yet more than 50 other countries have already launched national programs.

Hundreds of exemptions from active ingredient prescribing January 21, 2021

Active ingredient prescribing will be introduced from 1 February but recently published guidelines suggest a complex implementation with literally hundreds of partial or complete exemptions.

Mixed news for biosimilars in April price disclosure reductions January 21, 2021

The indicative price cuts for the 1 April 2021 price disclosure cycle have revealed mixed news on biosimilars with significant price cuts but only after several years.

Over 20 MS projects funded under new round of grants January 21, 2021

Twenty research projects focused on multiple sclerosis will receive a total of $2.9 million in grants under a program run by MS Research Australia and MS Australia.

Cystic fibrosis therapy the only one for alignment project in March January 21, 2021

TRIKAFTA (elexacaftor and tezacaftor and ivacaftor) is the only submission that will be considered at the March PBAC meeting under the new pilot that is investigating greater alignment with the regulatory process.

BioPharmaDispatch conference returns to May with a focus on 'challenges' January 20, 2021

The day's theme is 'challenges' against the backdrop of COVID-19, the 2021-22 Budget and the renegotiation of the federal government's existing industry agreements.

Investors back Chimeric Therapeutics on ASX debut January 20, 2021

A strong debut on the ASX for Chimeric Therapeutics with investors backing the company that is focused on the development of CAR-T cell therapies for solid tumours.

Latest Video

Most Read

COVID-19 vaccine manufacturing, supply and administration programs

Industry slams last minute Trump move to cut medicine coverage

This is what being 'among the first in the world' looks like

Hundreds of exemptions from active ingredient prescribing

Mixed news for biosimilars in April price disclosure reductions

New Stories

COVID-19 vaccine manufacturing, supply and administration programs

Bionomics-BMS combination completes trial treatment phase

Almac Group survey reveals pandemic impact on clinical trial activity

Industry slams last minute Trump move to cut medicine coverage

Queensland research institute in new cell therapy trial

This is what being 'among the first in the world' looks like

Hundreds of exemptions from active ingredient prescribing

Sign In

Latest Video

Most Read

COVID-19 vaccine manufacturing, supply and administration programs

Industry slams last minute Trump move to cut medicine coverage

This is what being 'among the first in the world' looks like

Hundreds of exemptions from active ingredient prescribing

Mixed news for biosimilars in April price disclosure reductions

Follow Us

New Stories

COVID-19 vaccine manufacturing, supply and administration programs

Bionomics-BMS combination completes trial treatment phase

Almac Group survey reveals pandemic impact on clinical trial activity

Industry slams last minute Trump move to cut medicine coverage

Queensland research institute in new cell therapy trial

This is what being 'among the first in the world' looks like

Hundreds of exemptions from active ingredient prescribing